Treatment outcomes stratified by baseline immunological status among young children receiving nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in resource-limited settings.
A study of 568 children aged <5 years who commenced nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in resource-limited settings revealed good early outcomes. After 12 months of antiretroviral therapy, survival probability was 0.89 (95% confidence interval, 0.86-0.92), with no significant difference among children stratified on the basis of baseline immunological levels; 62% attained a CD4 cell percentage >25%, and 7% continued to have a CD4 cell percentage <15%.
O'Brien
Daniel P
DP
AIDS Working Group, Médecins Sans Frontières, Paris, France. daniel.obrien@amsterdam.msf.org
Sauvageot
Delphine
D
Olson
David
D
Schaeffer
Myrto
M
Humblet
Pierre
P
Pudjades
Mar
M
Ellman
Tom
T
Zachariah
Rony
R
Szumilin
Elisabeth
E
Arnould
Line
L
Read
Tony
T
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000276:immunology* / Q000401:mortality; D018791:CD4 Lymphocyte Count; D002675:Child, Preschool; D003906:Developing Countries; D004359:Drug Therapy, Combination; D005260:Female; D006295:Health Resources / Q000600:supply & distribution*; D006801:Humans; D007108:Immune Tolerance; D008297:Male; D011336:Probability; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D016019:Survival Analysis; D016896:Treatment Outcome
D018894:Reverse Transcriptase Inhibitors